Roflumilast Use in COPD
Patient Selection Criteria
- The European Respiratory Society suggests that roflumilast should be used in patients with severe or very severe airflow obstruction and a history of exacerbations despite optimal inhaled therapy 1, 2
- Patients with chronic bronchitis phenotype and a history of exacerbations may benefit from roflumilast, according to the European Respiratory Society and the American College of Chest Physicians 1, 2, 3
- The Canadian Thoracic Society guideline recommends roflumilast for patients with chronic bronchitis phenotype at high risk of exacerbations who have moderate to high symptom burden and impaired lung function 4, 5
Clinical Benefits
- Roflumilast reduces the number of moderate or severe exacerbations per patient-year, with a rate ratio of 0.85 (95% CI 0.78-0.91), as reported by the European Respiratory Society 6
- Roflumilast decreases the proportion of patients who develop exacerbations, with a risk ratio of 0.85 (95% CI 0.78-0.94), according to the European Respiratory Society 6
- Roflumilast prolongs time to next exacerbation, with a hazard ratio of 0.88 (95% CI 0.81-0.96), as found by the European Respiratory Society 6
- Roflumilast modestly improves lung function, with increases in FEV1 and FVC, as reported by the European Respiratory Society 6
Common Side Effects and Precautions
- Patients receiving roflumilast are more likely to experience diarrhea, nausea, weight loss, psychiatric disorders, and sleep disturbance, with increased risk ratios, as reported by the European Respiratory Society 1, 7
- Higher discontinuation rates due to adverse effects occur with roflumilast compared to placebo, with a risk ratio of 1.80, according to the European Respiratory Society 1, 7